The Retiree Drug Subsidy (RDS) is a government-funded program that has historically been the go-to choice for plan sponsors who offer group health care coverage to retired employees. Established under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), its simplicity, limited member impact, and convenience made it a reliable option that financially supported plan sponsors in providing prescription drug benefits to their retiree populations.
However, the health care landscape has changed. Shifts in subsidies, changes within the pharmaceutical industry — such as the growth of biosimilars, gene therapies, and generic drugs — and adjustments to tax structures have diminished RDS' financial advantages. Furthermore, the impacts of the Inflation Reduction Act of 2022 (IRA) add further incentive for plan sponsors to explore RDS alternatives.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
